Empowered Funds LLC Invests $5.68 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Empowered Funds LLC bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 331,209 shares of the biotechnology company's stock, valued at approximately $5,680,000. Empowered Funds LLC owned 0.14% of ADMA Biologics at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics in the third quarter worth about $30,000. Larson Financial Group LLC purchased a new stake in ADMA Biologics in the third quarter worth about $31,000. GAMMA Investing LLC lifted its holdings in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the period. National Bank of Canada FI purchased a new stake in ADMA Biologics in the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics in the third quarter worth about $62,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ADMA has been the subject of several research analyst reports. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Stock Down 1.1 %

Shares of NASDAQ ADMA traded down $0.18 on Friday, reaching $15.90. 1,740,737 shares of the company's stock traded hands, compared to its average volume of 2,383,370. The company has a market cap of $3.76 billion, a price-to-earnings ratio of 56.79 and a beta of 0.75. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business's 50 day simple moving average is $17.27 and its two-hundred day simple moving average is $17.81. ADMA Biologics, Inc. has a 12 month low of $5.02 and a 12 month high of $23.64.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares of the company's stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.